Study of efficiency of the use of complex therapy of benign prostatic hyperplasia by medicine tamsulosin and Prostaplant Forte and Prostaplant


  • І. І. Горпинченко ГУ «Институт урологии НАМН Украины», г. Киев
  • Ю. М. Гурженко ГУ «Институт урологии НАМН Украины», г. Киев
  • В. В. Спиридоненко ГУ «Институт урологии НАМН Украины», г. Киев



Benign Prostatic Hyperplasia, treatment, tamsulosin, Prostaplant Forte, Prostaplant


The estimation of efficiency of the complex therapy by the medicines tamsulosin and Prostaplant Forte and Prostaplant in 37 patients with Benign Prostatic Hyperplasia of the second stage was carried out. The efficiency of the treatment has made 94,6%.

Author Biographies

І. І. Горпинченко, ГУ «Институт урологии НАМН Украины», г. Киев

I.I. Gorpinchenko

Ю. М. Гурженко, ГУ «Институт урологии НАМН Украины», г. Киев

Y.M. Gurzhenko

В. В. Спиридоненко, ГУ «Институт урологии НАМН Украины», г. Киев

V.V. Spiridonenkо


Возіанов О.Ф., Пасечніков С.П., Павлова Л.П. Досягнення і проблеми урологічної допомоги населенню України // Урологія. – 2001. – No 4. – С. 3–6.

Cockett A, Aso Y, Denis L 2nd Int.Consultation on Benign Prostate Hyperpalsia. – Paris, 1993.

Wolzt M, Fabrizii V, Dorner GT, Zanaschka G, Leufkens P, Krauwinkel WJ, and Eichler HG. Pharmacokinetics of tamsulosin in subjects with normal and varying degrees of impaired renal function: an open-label single-dose and multiple-dose study. Eur J Clin Pharmacol 1998; 54: 367–373.

Dunn CJ, Matheson A, and Faulds DM. Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging 2002; 19: 135–161.

Andersson KE. Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists. World J Urol 2002; 19: 390.

Chueh SC, Guh JH, Chen J, Lai MK, Ko FN, and Teng CM. Inhibition by tamsulosin of tension responses of human hyperplastic prostate to electrical field stimulation. Eur J Pharmacol 1996; 305:177–180.

Lowe FC. Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect. Clin Ther 1997; 19: 730–742.

Mann RD, Biswas P, Freemantle S, Pearce G, and Wilton L. The pharmacovigilance of tamsulosin: event data on 12484 patients. BJU. Int 2000; 85:446–450.

Shakir S, Pearce G, and Mann RD. Finasteride and tamsulosin used in benign prostatic hypertrophy: a review of the prescription-event monitoring data. BJU. Int 2001; 87: 789–796.

de la Rosette JJ, Kortmann BB, Rossi C, Sonke GS, Floratos DL, and Kiemeney LA. Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms. J Urol 2002; 167: 1734–1739.